Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag capsule versus tablet bioavailability and food-effect study in healthy adults
NL-OMON49500Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eltrombopag in Thrombocytopenia, sponsored by Novartis. Primary endpoints: AUClast, AUCinf and 6 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NL-OMON49500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49500.